To paraphrase Dr. Missling's statement in his first meeting with congress in 2015 -- 'We know what we have and we have no fear'

Power and Bas - Fred Knoll has 5.03% of Knoll Capital Management's funds invested in Anavex as of 12/31/2016, not 5% of Anavex's market cap.

Home > Hedge Funds > Knoll Capital Management > Profile
Hedge Fund - Knoll Capital Management
Get Email Alerts
ProfileHoldingsLatest 13D & 13G FilingsNews, Interviews, and Investor Letters
Fred Knoll Bio, Returns, Net Worth
Fred Knoll has led Knoll Capital Management since 1987, and he personally manages Knoll Capital Fund I and Knoll Capital Fund II. Fred Knoll had previously worked with Telos Corporation, General American Investors, Murray Johnstone, and Robert Fleming. He studied at M.I.T. and got his M.B.A. from Columbia University, and his fund focuses on technology stocks.

Share0 Tweet2
0 Share38
image: http://cdn1.insidermonkey.com/manager-images/no-pic.2014-03-02.png

Fred Knoll
Fund ProfileFiling Period:
Fund Name: Knoll Capital Management
Manager Fred Knoll
Portfolio Value $56,996,000
Change This QTR +1.00%
image: http://chart.apis.google.com/chart?cht=p&chd=t:13.27,86.65&chs=300x120&chl=Healthcare|Other&&chco=CB3A1B

Fund Holdings Sector Distribution
Top HoldingsLogin to See All Holdings | Sign up
Filing Period:
Last updated on February 14, 2017, 5:07 pm based on SEC 13F filings
No. Security Ticker Shares Value (x$1000) Activity % Port
1.
Corbus Pharmaceuticals Hldgs
2,563,925 $21,665 38.01%
2.
Abeona Therapeutics Inc
2,359,767 $11,445 +74% 20.08%
3.
Vascular Biogenics Ltd
860,605 $4,174 7.32%
4.
Anavex Life Sciences Corp
724,205 $2,868 5.03%

Read more at http://www.insidermonkey.com/hedge-fund/knoll+capital+management/466/#p1SHpScUXtXzrlMT.99

Maple had a little trouble with his geography three months ago also when he responded to Plato.
I would have hoped his handlers would have schooled him better by now.


drv17 Member Level Thursday, 01/05/17 10:25:40 AM
Re: Maple tree post# 86753
Post #
86760
of 101145 Go
Maple - You stated Austria in your post in January a portion copied here.

Remind all your contacts to VOTE !
Some forget or procrastinate which is what I found when I contacted them.
They were intending to vote but just hadn't got around to it. I told them that I would follow up if I didn't hear back from them.
We have to absolutely sure that the measures pass to support our outstanding BOD's recommendations.

I agree with Biostocks' reasoning in his post #9947 of the importance of the approval of this proposal.
To that end I have contacted everyone that I know personally that hold stock to encourage them to vote. I found a number of them that hadn't done so but all of them got right on it and voted. I suggest that all on this board that are in favor of this to contact those that they know holding to remind them to vote.

Thank you for the help. That will be much easier. I've used some of those but didn't think to look for that.
I have a tee shirt with a dog at a computer that says "OLD DOG LEARNING NEW TRICKS"

Sorry about all of the hyphens. I was trying to indicate a quote from Amstocks post and didn't know how to do it properly.

--------------------------------------------------------------------
Another variable much harder to determine is how individual genetic
differences impact the drug.
--------------------------------------------------------------------

I have been a participant Mayo Clinic's Biobank research since 2012 and have recently been contacted to participate
in a new study entitled "Right Drug, Right Dose, Right Time-Using Genomic Data to Individualized Treatment (Right Protocol)"
This is to be an open ended study with an additional 12,000 participant to the original 1013 participants in the original .

The clinic will put some genetic information in our medical records that will fall into two categories.
"1. Genetic variants that may affect how your body responds to certain prescription drugs."
"2. Other genetic factors that may be important to your health."

It appears that Anavex Life Science's team is ahead of the curve with their approach of looking at sub groups utilizing Ariana and Kem.

This is way over my head for sure. I await the response to BostonSportsNut's call for interpretation by the experts on the board.
Maybe it will be explained in the "Late Breaking Therapeutic Strategies in AD and PD" session Monday.

Thanks Ziggydmz1. I'll check it out.

Agreed Jimmy667. Seeing what Mr. Skarpelos "sacrificed " to hire Dr. Missling was a very large reason I felt comfortable investing in Anavex initially. I would really like to meet these gentlemen someday.

Kid - I'm not aware of what might be going on behind the scenes that could justify Dr. Missling's compensation package. Do you have any insight?
I have found a couple of people you might want to ask if this is reasonable or not. Here they are:


Tom Skarpelos
Mr. Skarpelos, a director of Anavex, is a self-employed investor with 17 years of experience working with private and public companies. For the past 10 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects.Mr. Skarpelos was engaged as a consultant to Anavex Life Sciences for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex Life Sciences, and is its largest shareholder.

Bernd Metzner, PhD
Bernd Metzner, PhD, a director of Anavex, is currently Chief Financial Officer of the Stroeer Group. Previously, he was Chief Administration Officer and member of the Board of Management of Bayer Schering Pharma AG, the pharmaceutical division of $100+ billion market cap company Bayer AG. In this position, Dr. Metzner had worldwide financial responsibility for the Bayer Pharma Group. During his almost 10-years with Bayer AG, Dr. Metzner also held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess, a specialty chemicals group. Dr. Metzner started his career at the law firm Flick Gocke Schaumburg and has a degree in business administration from the University of Siegen. After obtaining his doctorate, he became a chartered accountant.

I believe it was Feb. 17th Just checked here is the info.

Q: Who is entitled to vote at the 2017 Meeting?
A: Holders of Anavex Life Sciences Corp.’s common stock, par value $0.001 per share (“Common Stock”), at the close of
business on February 17, 2017, the record date for the 2017 Meeting (the “Record Date”) established by our board of
directors (the “Board”), are entitled to receive notice of the 2017 Meeting (the “Meeting Notice”), and to vote their shares
at the 2017 Meeting and any related adjournments or postponements thereof. The Meeting Notice, proxy statement and
form of proxy card are first expected to be made available to stockholders on or about March 10, 2017.
As of the close of business on the Record Date, there were 41,123,790 shares of our Common Stock outstanding and
entitled to vote. Holders of our Common Stock are entitled to one (1) vote per share at the 2017 Meeting. Holders of the
Common Stock are collectively referred to herein as the Company’s “stockholders.” At the 2017 Meeting, there will be a
total of 41,123,790 possible votes with respect to the outstanding shares of capital stock entitled to vote at the Meeting

Boston Sports Nut - you wanted to respond to a PM but don't have that privilege.
FYI - There is a "Happy Hour" every Friday afternoon. This is from the Handbook
What is Happy Hour? When is it?
Happy Hour is a one-hour block where everybody has the premium features enabled for them. You can do full-text searches, send private messages, read 100's of messages in one click, etc. All the groovy extras! Everything you see on the Feature Matrix. Happy Hour is every Friday, from 4-5pm EST.

I hope you are thinking of putting some in a Roth IRA to get the benefit of tax free gains which could be huge.

Buy out or Partnership ?
I noticed that all of the discussion lately has only been regarding buy out possibilities. It seems to me that the a series of partnerships with various BPs would result in maximizing returns to Anavex. This had been discussed previously at lengths on this board.
The poison pill could be put in place possibly to prevent any single BP from taking control of the entire platform.

Park West has done so.

Or... it already is a done deal back in September when Missling was awarded 500,000 options. The material transfer was made and a NDA is signed and AVXL has to observe a "Quiet Period".
Biogen could have gotten nervous that some other BP might make a hostile bid and foul up the AVXL/BIIB deal.
To prevent this from happening, Missling drafted the shareholders rights proposal.

What was interesting is that it was the last trade of the after hours. There were no further trades for the day.

Yesterday or day before (I'm going from memory) but after hours was down $0.24 ps on a couple thousand shares. I looked much later and it showed that it was back to the day close i.e. back up $0.24 ps on a trade of
One (1) whole share.
I tried to see if I could find the history on this but was unable to do so.
Extended trading only is meaningful if there is a relatively large trading volume. Otherwise it is FUD imo.

Biotechs - I agree. I have had that feeling for months. See my most recent post #82344 regarding my thoughts about something in the pipeline with Biogen. These events and the timing of them seem to be indicating some sort of an agreement in the works.

Very good article Talon. We had a suggested letter last time that people used and added their own input.
Maybe someone can get the ball rolling to start a letter writing campaign again. I don't have time right now.

Whiskey - This was encouraged last December and many people made the contacts. There were a lot of other good suggestion of groups to contact such as local and state alzheimers groups, Dr. Price head of Health and Human Services the new head of FDA, etc.

Here is the post at that time. This would be a good time for everyone renew this effort to keep hitting them with recent information.

Re: McMagyar post# 83348
Post #
83362
of 94275 Go
Mc - Suggestion to contact Senators and Representatives.
There are a couple of hundred posters on this board that could make an effective publicity campaign.
I suggested once before that a couple of posters collaborate and compose a very well documented informative piece and make it available for all of us to use so we could spread the news very widely. We could reach most of the 535 Senators and Congressmen and local State officials with solid information and stress the need to get this released as soon as possible.
Here is information on how to contact your elected officials.

How to Contact Your Elected Officials
Learn how to get in touch with your federal, state, and local elected leaders.

Contact Federal Elected Officials
President Barack Obama, Vice President Joe Biden and the White House - Contact the White House by submitting your comments or questions online or by phone or fax.
Members of the U.S. Congress
U.S. Senators - Get contact information for your senators in the U.S. Senate.
U.S. Representatives - Find the website and contact information for your representative in the U.S. House of Representatives.
Contact State Elected Officials
State Governors - Learn how to get in touch with your state governor.
State Legislators - Find the names and current activities of your state legislators.


( If you Google this the links will be effective. I don't know how to get them to you. Maybe a monitor could help . TIA)

I don't know why the funding question keeps arising. Dr. Missling has never misled us yet to my knowledge. He has a very strong Board of Directors that I would assume would not jeopardise their reputations by allowing him to mislead.
Perhaps by different ones bringing this question up is just a little FUD or soft bashing.

Here are some points presented numerous times on this board regarding funding.

From The Wall Street Transcripts interview :

Dr. Missling's answer to funding.
TWST: Do you have the financing you need to get through the development of ANAVEX 2-73 at this current stage?

Dr. Missling: Yes, we believe that sufficient financing in place and also because we are working with several foundations on specific diseases like the Michael J. Fox Foundation that has supported us very strongly for exploring ANAVEX 2-73 in a pre-clinical study of Parkinson’s disease, for which positive data was recently reported on September 22nd. And we also received support from the Rettsyndrome.org foundation, which also supported exploring ANAVEX 2-73 in a pre-clinical study in Rett syndrome, a rare disease for which Anavex received FDA orphan designation this year. We might continue these collaborations if the data continues to be promising.

Filed with SEC 10/21/16 This is superb Media coverage,
The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Managers

Filed with the SEC.
EX-99.1 2 s104371_ex99-1.htm EXHIBIT 99-1

Exhibit 99.1

Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp.

Australia information:

Funding? MacFarlane does the research at Caufield Hospital a unit of the Alfred Group in Australia. Here are some excerpts from Alfred Group's Annual Report 2015-16 published August 2016. This indicates that a great deal of funding comes from partnerships.

(Page 4 - Alfred Group annual Report 2015-16)

Chairperson and Chief Executive’s Year in Review (continued)

Discovering the next generation of care Partnerships continued to underpin significant research developments that informed clinical practice in Australia and overseas. Researchers from The Alfred answered the long-held debate over whether aspirin should be stopped before coronary artery surgery. The results of the 10-year international study showed no increased risk of surgical bleeding or need for blood transfusion associated with asprin use. Scientists from The Alfred and Monash University made a breakthrough in targeting aggressive blood cancers through combination therapy, giving hope to people suffering from Acute Myeloid Leukaemia. At our Caulfield campus, early research results from the international drug trial of Anavex 2-73, which aims to address the symptoms of dementia, were positive. Also significant was the announcement of PrEPX, a new public health research study supported by Alfred Health, the Victorian Government and the Victorian AIDS Council. This study will expand access to pre-exposure prophylaxis (‘PrEP’) medication to prevent HIV infection in people who are at high risk.


(Page 26 )
Research through partnership
This year’s achievements included care to prevent HIV infection, hope for those suffering severe asthma and dementia and a breakthrough in fighting blood cancer. We continued to attract a high level of funding from the National Health and Medical Research Council.


(Page 27)
Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims to address the symptoms of dementia, are positive. Trials at Caulfield Hospital are using Anavex, which, unlike current medications, is the only drug designed to both relieve symptoms and slow the disease’s progression. The first phase of the trial began in December 2014 and the next steps will involve further research with a larger group of participants in 2017.

My impression is that you can get the report by just clicking the first "HERE". It is a superb report imo.
He indicated to not click on the second "here". My interpretation is don't waste the $50.00

Great , Thank you Ven. I had the 31st date marked on my calendar but no other detail.

You need to work for the CIA. Good work.
I'm still going to dream anyway.

Thank you, I hate to admit it but I started looking at that long list and I convinced myself that Missling reporting on the 57 weeks results just shouldn't be an "additional speaker" and didn't look in the "M"s (LOL)

Lets see, so now a little 'pumping' speculation.
Anavex submitted that presentation to the conference and PR'd it, then the conference committee saw what he was going to present and decided that that would really be great to put in the slot " LATE BREAKING THERAPEUTIC STRATEGIES IN AD AND PD. So the committee told Anavex to remove their PR .

We can dream can't we ?

Thank you for the reminder. That is what I remembered and was looking for some detailed information on the AD?PK conference site. I have been telling people that is what was going to be reported, and I just wanted to be sure and not put out incorrect info.

13th annual Alzheimers and Parkinsons Conference
I could not find any information regarding Anavex participating. In doing a search, this is all I found:
......................................................................
Re: None
Post #
86542
of 93343 Go
About the 13th Alzheimers and Parkinson's conf in Vienna end of March, per their IR:

Anavex has not announced participation in the 13th International Conference on Alzheimer’s & Parkinson’s Diseases.

Please note that the company has an events page where updates are posted as they are announced: www.anavex.com/2016/?post_type=events.

Please do not hesitate to contact our office if we can be of further assistance.

On behalf of Anavex Life Sciences Corp.,
........................................................................


I do see a 2 hour slot on Sunday April 2 that would be a very nice slot for Dr. Missling to present his secrets.
Then come out with a nice PR on Monday morning April 3rd

11:45-13:45
DISSECTING THE MECHANISTIC CONNECTION BETWEEN
LYSOSOMAL DISEASES AND PD -

DISEASE MECHANISMS -

LATE BREAKING THERAPEUTIC STRATEGIES IN AD
AND PD -

IMAGING, BIOMARKERS AND TRANSLATIONAL ASPECTS

MICROGLIA AND INFLAMMATION

Xena and Android I don't know if this helps with your discussion but here is a previous post of excerpts from the Alfred Group's annual report. I infer from this that the Australian government will be involved again for the P3 they anticipated for 2017.

Post #
86394
of 92731 Go
Funding? MacFarlane does the research at Caufield Hospital a unit of the Alfred Group in Australia. Here are some excerpts from Alfred Group's Annual Report 2015-16 published August 2016. This indicates that a great deal of funding comes from partnerships.

(Page 4 - Alfred Group annual Report 2015-16)

Chairperson and Chief Executive’s Year in Review (continued)

Discovering the next generation of care Partnerships continued to underpin significant research developments that informed clinical practice in Australia and overseas. Researchers from The Alfred answered the long-held debate over whether aspirin should be stopped before coronary artery surgery. The results of the 10-year international study showed no increased risk of surgical bleeding or need for blood transfusion associated with asprin use. Scientists from The Alfred and Monash University made a breakthrough in targeting aggressive blood cancers through combination therapy, giving hope to people suffering from Acute Myeloid Leukaemia. At our Caulfield campus, early research results from the international drug trial of Anavex 2-73, which aims to address the symptoms of dementia, were positive. Also significant was the announcement of PrEPX, a new public health research study supported by Alfred Health, the Victorian Government and the Victorian AIDS Council. This study will expand access to pre-exposure prophylaxis (‘PrEP’) medication to prevent HIV infection in people who are at high risk.


(Page 26 )
Research through partnership
This year’s achievements included care to prevent HIV infection, hope for those suffering severe asthma and dementia and a breakthrough in fighting blood cancer. We continued to attract a high level of funding from the National Health and Medical Research Council.


(Page 27)
Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims to address the symptoms of dementia, are positive. Trials at Caulfield Hospital are using Anavex, which, unlike current medications, is the only drug designed to both relieve symptoms and slow the disease’s progression. The first phase of the trial began in December 2014 and the next steps will involve further research with a larger group of participants in 2017.

Agreed. This can be such a large platform that it is hard to fathom.
This has been addressed by you and a number of other posters previously.


(Sorry Xena, I was trying to correct the reference to the NWDR message #92558 and ran out of time while doing so and now it shows a blank. My response is now at #92750. I know that you being a great monitor can straighten it out. )

NWDR -Thank you. I haven't looked to find these reported estimate of cases myself.
Missling is doing a great job of keeping the dilution to a minimum which is very good news for longs. Even if the number of outstanding shares were to double, this would still result in a very nice pps.
More importantly though is that Anavex might be able to develop drugs to arrest or cure all of these terrible diseases including RETT Syndrome.

NWDR - Can you clarify these totals. I can't seem to come up with 20.7 million.

millions
AZ Epilepsy Parkinsons
US 5.3 2.2 1.0
EU 5.3 2.6 1.0
Japan 1.8 1.0 0.5

Total 20.7


Also the pps for a PE of 10 should be $705 shouldn't it?

The rules for recharacterization are complicated. I recommend discussing this with your CPA.
Also I believe that it is not necessarily based on the pps on April 15th but rather it is the date that you recharacterize but again your CPA is the best place to get personal advice.
BTW besides a penalty of $75.00 for late payment the interest charges are very reasonable.

Apparently I wasn't clear with my discussion. I agree with you regarding the Roth maneuvers.
I was trying to state that a person could wait for 6 months to decide then if staying with the conversion pay the taxes due and include the low rate of interest on that amount due.

Agreed, so it is just a gamble of percentages as I see it. The government's interest rate is quite low compared to potential gain of the conversion. This gives one the added time to make the decision whether to recharacterize or not.

You can also request an extension to file and you have until then to recharacterize your Roth conversion.

LOVE IT

"We think differently and we have no fear" Dr. Missling's words spoken in Washington D.C when asked why can Anavex succeed where so many failed.

Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
NEW YORK, NY – December 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been invited to speak at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event will take place on Tuesday, December 8, 2015 at the U.S. Capitol Visitor Center in Washington, D.C.